Products List

Walvax has successfully developed 8 licensed vaccines, including 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) and Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (HPV2).

In August 2024, HPV2 was successfully pre-qualified by WHO. This certification indicates that the vaccine's safety, efficacy, and quality control meet WHO standards and that the production management system of our facility complies with WHO Good Manufacturing Practices (GMP) requirements.

Quick Links

Pipeline

All Products Pneumococcal Vaccine Series Meningococcal Vaccine Series Other Vaccines

Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)

Package Insert

For the prevention of cervical cancers and precancerous lesions caused by human papillomavirus types 16/18.

Haemophilus Influenzae Type b Conjugate Vaccine

Package Insert

Prevention of invasive infections caused by Haemophilus Influenzae type b for infants and children 2 months through 5 years of age.

Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, adsorbed

Walvax沃森生物

Products List

Walvax has successfully developed 8 licensed vaccines, including 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) and Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (HPV2).

Prevention of invasive infections caused by Haemophilus Influenzae type b for infants and children 2 months through 5 years of age.

Prevention of pertussis, diphtheria and tetanus for infants and children 3 months through 6 years of age.